NCT02843074 2023-12-05Elotuzumab, Lenalidomide and Dexamethasone in Treatment of Transplant-Eligible Newly Diagnosed Multiple Myeloma PatientsSCRI Development Innovations, LLCPhase 2 Completed53 enrolled 14 charts
NCT00742560 2018-01-10A Phase 1b/2, Dose-Escalation Study of Elotuzumab (Humanized Anti-CS1 Monoclonal IgG1 Antibody) in Relapsed Multiple MyelomaAbbViePhase 2 Completed101 enrolled 20 charts